, Volume 187, Issue 4, pp 397–404

Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats

  • Olga A. Dravolina
  • Wojciech Danysz
  • Anton Y. Bespalov
Original Investigation

DOI: 10.1007/s00213-006-0440-1

Cite this article as:
Dravolina, O.A., Danysz, W. & Bespalov, A.Y. Psychopharmacology (2006) 187: 397. doi:10.1007/s00213-006-0440-1



Metabotropic glutamate receptors (mGluRs) were reported to regulate various behavioral effects of addictive drugs.


The present study evaluated the role of group I mGluRs in the progressive augmentation (“sensitization”) of the behavioral effects observed after repeated, intermittent cocaine exposure.

Materials and methods

After habituation to handling and baseline activity measurement (days 1–2), rats received eight injections of cocaine (10 mg/kg) or saline on days 3–6, 8–11, and then, were tested twice with acute saline and cocaine given in a counterbalanced manner on days 13 and 15. Before the test sessions, subjects were pretreated with mGluR1 antagonist EMQMCM (JNJ16567083, (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate) and mGluR5 antagonist MTEP ([(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine).


Pretreatment with EMQMCM (2.5–10 mg/kg) but not MTEP (2.5–10 mg/kg) significantly reduced expression of the sensitized ambulatory motor activity of the cocaine-experienced animals acutely challenged with cocaine. Both EMQMCM and MTEP significantly reduced vertical motor activity across all cocaine/saline treatment conditions.


These findings indicate that the expression of behavioral sensitization to cocaine-induced stimulation of locomotor activity may be modulated by group I mGluR antagonists (mGluR1 rather than mGluR5), but these effects occur at the dose levels that attenuate vertical activity.


Cocaine Motor activity Sensitization Conditioning Metabotropic glutamate receptor antagonist Rat 

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Olga A. Dravolina
    • 1
  • Wojciech Danysz
    • 2
  • Anton Y. Bespalov
    • 1
  1. 1.Laboratory of Behavioral Pharmacology, Institute of PharmacologyPavlov Medical UniversitySt. PetersburgRussia
  2. 2.Preclinical R&DMerz PharmaceuticalsFrankfurt am MainGermany
  3. 3.CNS PharmacologyAbbott GmbH & Co. KGLudwigshafenGermany

Personalised recommendations